LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

3.31 -2.93

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.1

Максимум

3.52

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	341
EBITDA	-44M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+69.49% upside

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	27M 149M
Предишно отваряне	6.24
Предишно затваряне	3.31

Настроения в новините

By Acuity

54%

46%

263 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.03.2026 г., 19:18 ч. UTC

Значими двигатели на пазара

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11.03.2026 г., 23:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

11.03.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11.03.2026 г., 23:51 ч. UTC

Пазарно говорене

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11.03.2026 г., 23:41 ч. UTC

Пазарно говорене

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11.03.2026 г., 22:29 ч. UTC

Пазарно говорене

Australia Shares Set to Fall in Early Trade -- Market Talk

11.03.2026 г., 21:47 ч. UTC

Печалби

Liontown Resources: Market Tailwinds Strengthening Outlook

11.03.2026 г., 21:46 ч. UTC

Печалби

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11.03.2026 г., 21:45 ч. UTC

Печалби

Liontown Resources Says FY26 Guidance Unchanged

11.03.2026 г., 21:45 ч. UTC

Печалби

Liontown Resources 1H Unit Operating Costs A$985/Ton

11.03.2026 г., 21:44 ч. UTC

Печалби

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11.03.2026 г., 21:43 ч. UTC

Печалби

Liontown Resources 1H Revenue A$207.5 Million

11.03.2026 г., 21:43 ч. UTC

Печалби

Liontown Resources 1H Net Loss A$184 Million

11.03.2026 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11.03.2026 г., 21:10 ч. UTC

Печалби

Vista Gold FY25 Loss $7.5M >VGZ

11.03.2026 г., 21:10 ч. UTC

Печалби

Vista Gold FY25 Loss/Shr 6c >VGZ

11.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.03.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11.03.2026 г., 20:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11.03.2026 г., 20:19 ч. UTC

Значими събития в новините

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11.03.2026 г., 20:15 ч. UTC

Печалби

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11.03.2026 г., 19:31 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11.03.2026 г., 19:01 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11.03.2026 г., 18:59 ч. UTC

Придобивния, сливания и поглъщания

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11.03.2026 г., 18:43 ч. UTC

Значими събития в новините

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

69.49% нагоре

12-месечна прогноза

Среден 4 USD 69.49%

Висок 4 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

263 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.